Payers, providers, patients and pharmaceutical companies are all interested in understanding the value of specific treatments protocols, whether these rely on medications, medical devices or other treatment modalities. Additionally, there are different axes on which value can be measured, starting with traditionally defined clinical endpoints, but increasingly relying on genomic, financial and patient experience endpoints.
The problem is that the ability to compile large, robust datasets of deep phenotypic and genotypic information, supplemented by financial and patient reported outcome (PRO) data, does not exist on a national or global basis. While there are numerous registries that are collecting increasing amounts of deep clinical data, these are very manually intensive and rarely connected to other data sources.
The solution is what our experts refer to as the "registry of the future;" a registry that leverages large quantities of data and innovative technology to provide the real-world evidence required to answer the questions asked by multiple stakeholders.
Brian Kelly, M.D., President Payer and Provider Solutions
Jason Colquitt, VP, IT, Head of RWLP IT, Global Business Solutions Operation
Biopharmaceutical and device contacts with titles related to Associations, safety, post-approval, post-marketing, regulatory affairs, medical affairs